Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Feigelson, Heather Spencer, Zeng, Chan, Pawloski, Pamala A., Onitilo, Adedayo A., Richards, C. Sue, Johnson, Monique A., Kauffman, Tia L., Webster, Jennifer, Nyirenda, Carsie, Alexander, Gwen L., Hwang, Clara, Cross, Deanna, McCarty, Catherine A., Davis, Robert L., Schwarzkopf, Denise, Williams, Andrew E., Honda, Stacey, Daida, Yihe, Kushi, Lawrence H., Delate, Thomas, Goddard, Katrina A. B.
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2014
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4006772/
https://ncbi.nlm.nih.gov/pubmed/24788807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0094977
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы